



NCCTG

NORTH CENTRAL CANCER TREATMENT GROUP

Date: July 27, 2007

To: Primary Clinical Research Associates

From: Janis Wobschall
Protocol Development Coordinator

Re: N0572: A Phase I/II trial of Sorafenib and CCI-779 in Recurrent Glioblastoma

The Pathology Submission Form has been revised as follows:

- Clarification that form is used to update the Outstanding Materials Report has been added to the header
- Time point of form submission defined
- “Date sent:” changed to “Date specimen shipped:”
- Reviewer (name) and Membership of Reviewer (location) were combined to one line which collects both name of reviewer(s) and location(s)
- Contact information box added

If you have any questions, please feel free to contact me at 507/284-4852.

JW/dg
Enclosure